Biologicaltherapy cycles

 

towards tailored, needs-driven, safer and
cost-effective management of Crohn’s disease.

This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633168 – BIOCYCLE (PHC-13-2014).

Objective

The objective of the BIOCYCLE project is to assess long-term treatment strategies in Crohn’s disease that will improve both safety and related costs while ensuring a constant level of efficacy during maintenance therapy.

Crohn’s disease is a chronic longstanding disease that can’t be cured with current available treatments. The aim of long-term treatment is to fully control the symptoms and avoid the progression of intestinal damage. Currently, the preferred strategy for moderate-severe disease is a combination therapy with anti-TNFα and anti-metabolites (immunosuppressant). This long-term treatment may lead to cost and safety issues. The BIOCYCLE action will assess the efficacy, safety, effectiveness and feasibility of either anti-TNFα or immunosuppressant withdrawal in those patients.

Project overview

Crohn’s disease

Treatment

Curative therapies do not yet exist and the current best treatments are symptoms relieving therapies. The drug of choice and treatment strategies depend on the clinical characteristics and severity of the disease.

Mild disease may be treated by mesalazine or no treatment with limited number of courses of topical steroids.

The gold standard of care for moderate to severe Crohn’s disease is the Combo therapy, the uninterrupted combination of anti-TNFα monoclonal antibodies and immunosuppressant. However, this kind of treatment raises safety and costs issues.
Indeed, anti-TNFα is the most expensive medication and potential adverse effects are associated with the Combo therapy, namely cancers and possible increase of severe infections. In addition, patients are exposed to class-specific drug complications.

Description of the disease

Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) affecting the gastro-intestinal tract. CD often begins at young age and lasts the whole life. The prevalence is 20-30% higher for women than for men.

CD is characterized by a sequence of active disease episodes (flare-ups) and remissions of variable duration. The chronicity of CD has a significant impact on patients’ quality of life (QoL).

Genetic susceptibility, modified composition of the gut microbiota and impaired function of the mucosal immune system are the main known contributors to the etiology of CD. However, the primary cause remains unknown.

Partners

The BIOCYCLE project involves a consortium between 13 partners.

NEWS FROM BIOCYCLE

ECCO, a partner of the BIOCYCLE project, has dedicated pages 16 to 17 of its ECCO News Volume 12, Issue 2, 2017 to the BIOCYCLE project, providing information on BIOCYCLE progresses (ECCO News).

The BIOCYCLE project has now been ongoing for almost 2 years. This project, funded by the European Commission under the Horizon 2020 program, aims at exploring different aspects of the question of treatment de-escalation in moderate to severe Crohn’s Disease, the control of which first requires a […]

view more

An international research project in which you can be a stakeholder

Association François Aupetit (AFA), a partner of the BIOCYCLE project, has dedicated pages 16 to 17 of its magazine to the project to collect Crohn’s Disease Patients’ opinion regarding their preference and benefits/risks perspectives on Combo Therapy using anti-TNF/immunossuppressant medications.

AFA Magazine

 

view more